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Background
The impact of HLA matching on outcomes of unrelated donor (URD) hematopoietic stem 
cell transplantation (HSCT) varies in different racial or ethnic groups. Since little is known 
about the impact of such matching on URD HSCT in Korean children, we analyzed this 
issue. 
Methods
We analyzed the outcomes of 142 patients who underwent URD HSCT at 4 Korean medi-
cal centers. All patient donor pairs were fully typed for HLA-A, -B, -C, and -DR alleles. 
Results
At a median follow-up of 22 months, 3-year survival rates for patients with 8, 7, and ≤
6 matched alleles were 88.4%, 70.7%, and 53.6%, respectively. A single mismatch (Mm) 
at HLA-B or -C was associated with lower survival compared with that associated with 
8 matched alleles. No significant differences were observed between single-allele and 
single-antigen Mms with respect to survival rate or acute graft-versus-host disease 
(aGVHD) incidence rates. HLA disparity had a greater impact on the survival of patients 
with high-risk malignancy than of those with low-risk malignancy. Among pairs with a 
single Mm, only locus A showed a significant association and higher risk of grade III-IV 
aGVHD compared to those in patients with 8 matched alleles. 
Conclusion
Disparity in HLA class I, regardless of antigen or allele Mm, adversely affected both survival 
and grade III-IV aGVHD development. An increased number of HLA Mms was associated 
with a higher risk of post-transplantation complications. Further investigations using larg-
er cohorts are required to confirm the effects of HLA mismatching on URD HSCT patient 
outcomes.
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INTRODUCTION
  Allogeneic hematopoietic stem-cell transplantation (HSCT) 
is a well-established curative therapy for the treatment of 
lymphohematopoietic and congenital metabolic disease. Be-
cause there is a lack of HLA-identical related donors in 
approximately 75% of the cases, during the past few years, 
an increasing number of HSCTs have been performed using 
HLA-matched unrelated donors (URDs) [1]. Employment 
of URD introduces a number of questions and problems 
in donor selection that do not occur in transplantation from 
an HLA-identical sibling donor. The precise impact of HLA 
mismatching on HSCT outcomes remains unclear, because 
studies on the relative importance of various loci involved 
have yielded different results. Nearly every HLA locus has 
been reported to influence the outcome of URD HSCT; how-
ever, conflicting data have been obtained [2-4]. In American 
patients, a single mismatch (Mm) at HLA-B or -C was better 
tolerated than those at HLA-A or -DRB1 [5]. In Japanese Korean J Hematol 2011;46:11-7.
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Table 1. Patient characteristics.
Characteristics N % Median (range)
Age at transplantation (mo) 98 (4-244)
Patient gender (Male/Female) 85/57 60/40
Disease
 ALL
 AML
 AmixL
 ABL
 JMML
 MDS
 CML
 SAA
 Lymphoma
 HLH
 Others
a)
33
52
2
9
3
5
3
18
2
3
12
23
37
1
6
2
4
2
13
1
2
8
Disease status
 Low risk
 High risk
 Nonmalignant disease
71
38
33
50
27
23
ATG as GVHD prophylaxis
 Yes
 No
84
58
59
41
Conditioning intensity
 Reduced intensity
 Myeloablative
46
96
32
68
Source of stem cells
 Bone marrow
 Peripheral blood
69
73
49
51
Total body irradiation
 Yes
 No
37
105
26
74
Patient / Donor CMV status
 +/+
 +/−
 −/+
 −/−
116
11
11
2
82
8
8
1
a)Others include Fanconi anemia (6 patients), pure red cell anemia
(1 patient), congenital dyserythropoietic anemia (1 patient), Wiskott-
Aldrich syndrome (1 patient), Krabbe disease (2 patients), and 
adrenoleukodystrophy (1 patient).
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute 
myeloid leukemia; AmixL, acute mixed lineage leukemia; ABL, 
acute basophilic leukemia; JMML, juvenile myelomonocytic 
leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid
leukemia; SAA, severe aplastic anemia; HLH, hemophagocytic 
lymphohistiocytosis; ATG, antithymocyte globulin; GVHD, graft 
versus host disease; CMV, cytomegalovirus.
patients, however, the presence of a HLA-A or -B Mm signifi-
cantly reduced survival, whereas a Mm at HLA-C or -DRB1/ 
DQB1 did not [6]. Molecular typing techniques for all HLA 
loci have demonstrated that serological matching is in-
sufficient to ensure an allelic match [7, 8]. High-resolution 
DNA-based typing of HLA alleles has markedly improved 
donor selection accuracy, resulting in improved HSCT pa-
tient outcomes. However, the relative importance of anti-
genic and allelic Mms remains unclear [5, 9]. 
  The impact of HLA Mms on disease outcomes in Korean 
children has not been determined, and the relationship be-
tween Mms and disease status has not been explored. We, 
therefore, retrospectively assessed the impact of high-reso-
lution donor-recipient matching results at the HLA-A, -B, 
-C, and -DR loci on patient outcomes in 142 Korean children 
treated with URD HSCT.
MATERIALS AND METHODS
1. Patients
  This study included 142 patients aged ≤18 years, who 
received HSCT from URDs at 4 medical centers (Asan 
Medical Center, Seoul National University Hospital, Samsung 
Medical Center, and National Cancer Center) in Korea be-
tween April 2003 and September 2009. The median follow-up 
duration was 22 months (range, 1-78 months).
  All patient-donor pairs were fully typed for HLA-A, -B, 
-C, and -DR alleles. Details of the study population are shown 
in Table 1. Underlying malignant diseases included acute lym-
phoblastic leukemia (ALL), acute myeloid leukemia (AML), 
non-Hodgkin’s lymphoma (NHL), myelodysplastic syndrome 
(MDS), and chronic myeloid leukemia (CML). Nonmalignant 
diseases included bone marrow failure, immunodeficiency, 
hemophagocytic lymphohistiocytosis, and metabolic disease. 
Patients with hematological malignancies were divided into 
low-risk and high-risk subgroups based on disease status 
at transplantation. Low-risk individuals had ALL or AML 
in first complete remission (CR), MDS with either refractory 
anemia or refractory anemia with ringed sideroblasts sub-
types, or CML in first chronic phase (CP). All other hemato-
logic malignancies were considered high risk. Seventy-one 
patients were classified as low-risk and 38 as high-risk.
 Stem cell sources included bone marrow in 69 (49%) and 
granulocyte colony-stimulating factor (G-CSF) mobilized pe-
ripheral blood in 73 (51%) patients. Recipients of cord blood 
were excluded in this study, because HLA Mms may have 
a different impact in this patient population. 
2. HLA typing and matching
  All donors and recipients were HLA-typed both serologi-
cally and using PCR by using sequence-specific primers 
(SSPs), and all donor-recipient pairs were fully typed for 
HLA-A, -B, -C, and -DR using high-resolution molecular 
typing. All Mms were classified according to the loci involved 
and whether they were detected at the low- or high-reso-
lution level.
3. Definitions of outcomes
  The primary outcome was overall survival (OS), defined 
as the time from graft infusion to death from any cause. 
Treatment-related mortality (TRM) was defined as death du-
ring continuous CR of the primary disease. Secondary end-
points included neutrophil engraftment, defined as timing 
of the first 3 consecutive days on which a patient had neu-
trophil counts ＞0.5×10
9/L, the cumulative incidence of 
grades II-IV acute graft-versus-host disease (aGVHD), and 
the cumulative incidence of relapse in patients with malig-
nant disease. aGVHD was diagnosed and graded using estab-
lished criteria [10]. Patients were considered evaluable for 
engraftment, if they survived for at least 21 days after HSCT. Korean J Hematol 2011;46:11-7.
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Table 2. High-resolution HLA mismatch characteristics in 142 
donor-recipient pairs.
8/8 (%)
N=59
7/8 (%)
N=56 
6/8 (%)
N=20
≤5/8 (%)
N=7
Allele match 59 (100) 0 0 0
Single allele Mm 0 25 (45) 0 0
2 allele Mm 0 0   6 (30) 0
3 or more allele Mm 0 0 0 1 (14)
Single antigen Mm 0 31 (55) 0 0
2 antigen Mm 0 0 1 (5) 0
3 or more antigen Mm 0 0 0 1 (14)
Single antigen+single allele Mm 0 0 13 (65) 0
Single antigen+2 allele Mm 0 0 0 4 (57)
Single antigen+3 allele Mm 0 0 0 1 (14)
Abbreviation: Mm, mismatch.
Table 3.  Cox regression analysis of overall survival.
Variable HR 95% CI P
High-resolution HLA matching
 Matched for all 8 loci
 1 locus Mm
 ≥2 loci Mm
1
2.94
6.07
1.04-8.32
1.94-19.01
0.04
0.002
Patient age (years)
 Younger than 5 years
 5-10 years
 Older than 10 years
1
0.92
1.69
0.31-2.76
0.63-4.54
0.89
0.29
Gender Mm
 Match
 Mm
1
1.04 0.47-2.32 0.92
Conditioning regimen 
 Reduced intensity conditioning
 Myeloablative conditioning
Stem cell source
 Bone marrow
 Peripheral blood
1
9.52
1
1.67
2.16-41.94
0.74-3.77
0.003
0.22
Disease status at HSCT
 Low risk
 High risk
 Non-malignant disease
1
2.12
0.56
0.87-5.15
0.17-1.86
0.09
0.35
Abbreviations: HR, hazard ratio; Mm, mismatch; HSCT, hemato-
poietic stem cell transplantation.
Table 4. Adjusted hazard ratios of HSCT outcomes according to total number of HLA mismatches.
No.
Overall survival Transplant-related mortality Acute GVHD Grade II-IV
HR 95% CI P HR 95% CI P RR 95% CI P
8/8 matched 59 1 1 1
7/8 matched
 A locus Mm
 B locus Mm
 C locus Mm
 DR locus Mm
≤6/8 matched
56
13
3
29
11
27
2.94
3.93
17.67
3.37
0.00
4.42
1.04-8.32
0.92-16.72
2.08-52.61
1.12-9.32
0.00
1.63-11.97
0.04
0.06
0.03
0.04
0.99
0.003
3.39
4.68
17.5
3.73
0.00
5.45
1.06-10.85
0.41-15.38
3.13-98.42
1.05-13.23
0.00
1.68-17.7
0.05
0.08
0.01
0.06
0.99
0.005
2.12
3.03
1.77
2.16
1.33
6.02
0.94-4.82
0.87-10.61
0.15-21.01
0.82-5.71
0.31-5.73
2.23-16.26
0.07
0.08
0.65
0.12
0.71
0.00
Abbreviations: HSCT, hematopoietic stem cell transplantation; Mm, mismatch; HR, hazard ratio; RR, relative ratio.
Relapse-related death was defined as death caused by relapse 
after HSCT, regardless of any further treatment for relapse.
4. Statistical analysis
  Continuous variables are expressed as median (range), 
whereas categorical variables are expressed as proportions 
and/or percentages. Descriptive statistical analysis was per-
formed to compare patient baseline and post-transplantation 
characteristics. Two-sided Fisher’s exact test was used in 
2×2 table analysis. OS curves were calculated using Kaplan- 
Meier method and compared using the log-rank test. Cumula-
tive incidence curves for TRM and relapse with or without 
death were constructed to reflect the time to relapse and 
time to transplant-related death as competing risks. Cumulative 
incidences were compared using Gray’s test. Both analyses 
were performed using Cox regression for OS, TRM and re-
lapse-related death, and logistic regression for aGVHD and 
engraftment. Variables considered included HLA match, pa-
tient age, donor-recipient gender match, disease status, stem 
cell source, and intensity of conditioning. All reported P-val-
ues are 2-sided, and P-value of ＜0.05 was considered statisti-
cally significant. All statistical analyses were performed using 
SPSS Version 18.0 software program or R 2.10.1.
RESULTS
1. Types of HLA Mms present in the study population
  Match/Mm characteristics of the 142 donor-recipient pairs 
are summarized in Table 2. High-resolution typing (4-digit 
level) revealed that 59 (41.5%) of donor-recipient pairs 
matched at all 8 loci, 56 (39.4%), had 1 HLA-A, -B, -C, 
or -DR Mm, 20 (14.1%), had 2 Mms, and 7 (4.9%) had 
3 or more Mms at these loci. Of the 56 single-locus Mms, 
25 (44.6%) were detectable upon low-resolution typing and 
31 (55.4%) on high-resolution typing. 
2. Overall survival 
  The 3-year OS in all patients was 74.1±4.0%. Univariate 
estimates of OS are shown in Table 3. Using multivariate 
analysis, HLA matching was shown to be the most significant 
factor associated with mortality.Korean J Hematol 2011;46:11-7.
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  Mm at a single locus was associated with a lower survival 
rate than was observed for 8/8 HLA-matched pairs. Table 
4 shows the association between HLA Mm and survival. 
A single Mm at HLA-B, or -C was associated with a sig-
nificantly lower survival rate compared to that of patients 
with 8 matched alleles, whereas a single Mm at HLA-A 
or DR was not. Risks associated with single allele vs. single 
antigen Mms with regard to OS were not statistically 
significant. An increase in the number of HLA Mms was 
associated with reduced OS (Fig. 1A). The 3-year survival 
rates for patients with 8, 7, and ≤6 matched alleles were 
88.4%, 70.7%, and 53.6%, respectively (P=0.006). There was 
a significant survival difference between patients with 8 
and 7 matched alleles (P=0.015); however, there was no 
significant survival difference between patients with 7 and 
≤6 matched alleles (P=0.39). 
  We also evaluated the association between the number 
of HLA-Mms and survival in patients with high- or low-risk 
hematologic malignancies (Fig. 1B and C). HLA Mms had 
a significantly greater effect on the survival of patients with 
high- compared to low-risk malignancies (P=0.003). The 
adjusted OS hazard ratios for pairs of patients with single 
Mms compared to those for high-risk and low-risk patients 
with 8 matched alleles were 12.14 (95% CI=1.13-123.62, 
P=0.04) and 1.24 (95% CI=0.32-4.86, P=0.76), respectively.
3. Engraftment
  In this study, 136 of the 142 patients (95.8%) underwent 
successful graft procedures. The median time to neutrophil 
engraftment was 14 days (range, 9-35 days). Six patients 
(4.2%) showed graft failure; 4 had malignant diseases, and 
2 had non-malignant diseases. There was no association be-
tween the numbers of HLA Mms (either allele or antigen) 
and engraftment.
4. Acute GVHD
  The overall incidences of grade II-IV aGVHD for patients 
with 8, 7 and ≤6 matched alleles were 22.0%, 37.5%, and 
63.0%, respectively. Additionally, the incidences of grade 
III-IV aGVHD in these 3 groups were 6.8%, 23.2%, and 
33.2%. An increased number of HLA Mms was associated 
with an elevated risk of grade III-IV aGVHD (P=0.003). 
No significant difference was observed in aGVHD incidence 
between a single high- and a single low-resolution Mm.
  Although a single locus Mm was not significantly associated 
with grade II-IV aGVHD, the incidence of grade II-IV 
aGVHD was significantly higher in recipients with ≥2 Mm 
than in recipients with 8 matched alleles (Table 4). Among 
pairs with a single locus Mm, only those in whom the Mm 
was at HLA-A were at a significantly higher risk of grade 
Fig. 1. Kaplan-Meier estimates of overall survival relative to 
HLA-matching status in all patients (A) and in patients with high 
risk (N=38) (B) and low risk (N=71) (C) hematologic mali-
gnancies.Korean J Hematol 2011;46:11-7.
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Fig. 2. Cumulative 3-year incidence of transplant-related mor-
tality in all patients (A) and in patients with high risk (N=38) (B) 
and low risk (N=71) (C) hematologic malignancies.
III-IV aGVHD (RR=8.59, 95% CI=1.89-38.88, P=0.005), al-
though a single Mm at locus C generally increased the risk 
of grade III-IV aGVHD, with borderline statistical sig-
nificance (RR=3.59, 95% CI=0.93-13.91, P=0.06). Other sig-
nificant non-HLA factors present in the multivariate model 
included stem cell source (P=0.05) and conditioning regimen 
(P=0.003).
5. Relapse/Relapse-related death
  The 3-year cumulative incidence of relapse in patients 
with malignancies was 21.7±0.3%. There was no association 
between the numbers of HLA Mms (either allele or antigen) 
and relapse, or between HLA matching status and relapse-re-
lated death. According to multivariate analysis, no non-HLA 
factor was associated with relapse.
6. Transplant-related mortality
  The 3-year cumulative incidence of TRM is shown in 
Fig. 2A. The major cause of TRM was infection. TRM in-
cidence was significantly higher in recipients with a single 
Mm at the HLA-B locus than in those with a single Mm 
at the other loci, HLA-A, -C, or -DR (33.3 vs. 19.4%, P= 
0.007); among 3 patients with HLA-B Mm, 2 died of TRM, 
including veno-occlusive disease and infection.
  Associations between the number of HLA-Mms and TRM 
in patients with high- and low-risk hematologic malignancies 
are illustrated in Fig. 2B and C. The number of HLA Mms 
had a significantly greater effect on TRM in patients with 
high-compared to low-risk disease (P=0.002). Compared 
with adjusted hazard ratios of TRM for recipients with 8 
matched alleles, the adjusted hazard ratios of TRM for recipi-
ents with ≤6 matched alleles were 51.0 (95% CI=3.89- 
669.41, P=0.003) in patients with high-risk disease and 2.55 
(95% CI=0.44-14.59, P=0.29) in patients with low-risk 
disease. Multivariate analysis identified donor/patient gender 
Mm (P=0.04) and conditioning regimen (P=0.02) as sig-
nificant non-HLA factors associated with TRM.
DISCUSSION
  Extensive recent research has shown that mismatches at 
each HLA locus can affect clinical outcomes of patients un-
dergoing URD HSCT [11-13]. The role of HLA on HSCT 
outcomes had not previously been assessed in Korean chil-
dren; thus, we evaluated the effects of patient-donor HLA 
compatibility in these children. This is the first multicenter 
study to analyze the relative clinical importance of HLA 
matching on major transplantation outcomes in Korean chil-
dren. Several important results emerged from our analysis.Korean J Hematol 2011;46:11-7.
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  First, there were no differences in survival, aGVHD, and 
relapse when single allele and single antigen Mms were 
compared, in contrast to the common perception that allele 
Mms are better tolerated than are antigen Mms. Previous 
studies have reported conflicting results, with single allele 
and antigen Mms showing either equivalent [4, 5, 9] or 
different [14] effects on outcomes. Although particular high- 
resolution Mms have been regarded as more permissive than 
their low-resolution counterparts, data on pooled high-reso-
lution Mms showed that adverse effects on transplantation 
outcomes were detectable [14]. Our results suggest that both 
low- and high-resolution Mms should be considered equiv-
alent when determining optimal donor-patient HLA matches. 
However, our inability to detect significant differences may 
be because the donor-recipient population in this study was 
relatively small.
  Our results demonstrate the negative effects of a single 
Mm on survival. Some Mms exhibit worse transplant out-
comes than other Mms. A recent National Marrow Donor 
Program (NMDP) study [14] found that single Mms at 
HLA-A, -B, -C, and -DR loci had similar adverse effects 
on mortality, and other reports have described a deleterious 
effect of HLA-C Mms on survival [3, 14, 15]. In this study, 
we found that single Mms at HLA-B and -C, but not at 
HLA-A and -DR, were associated with significantly lower 
survival rates, compared to those in patients with 8 matched 
alleles. These findings agree with the hypothesis that Mms 
at some loci are better tolerated than those at the others. 
As the strong linkage disequilibrium between HLA-B and 
-C results in frequent coordinate matching, information on 
both loci is of importance in determining optimal do-
nor-patient HLA matches [16]. Moreover, HLA-A Mms are 
associated with a significantly higher risk of grades III-IV 
aGVHD. Although reports have yielded different results 
when the association between HLA disparity and aGVHD 
were compared, our findings confirm that HLA-A Mms have 
significant adverse effects on severe aGVHD [14].
  An elevated number of HLA Mms also increased the risk 
of post-transplantation complications, including poorer over-
all survival, TRM, and aGVHD incidence and severity. In 
this study, each additional Mm was associated with a 17-18% 
absolute decrease in survival. Most previous studies have 
shown that multiple Mms increase mortality and the risk 
of post-transplantation complications. 
  Notably, the impact of HLA Mms differed among patients 
at various stages of disease. Some previous studies have re-
ported that high-risk disease before HSCT had a greater 
absolute impact on survival than did HLA mismatching [5, 
9, 15]. In this study, however, the impact of single HLA 
Mms on survival was more detrimental in patients with 
high- compared to low-risk malignancies. These differences 
may be due to higher incidence of grade III-IV aGVHD 
(P=0.05) and the use of a myeloablative conditioning regimen 
(P=0.01) in high-risk malignancies compared to those in 
low-risk malignancies; differences may also reflect higher 
intensities of immunosuppression and the tendency to have 
an infection. We also found that TRM rates were proportional 
to the extent of HLA mismatching in both the high- and 
low-risk disease categories; thus, the greater impact of single 
Mms on survival in patients with high- rather than low-risk 
disease is likely attributable to augmentation in patients with 
higher-risk disease of the negative effect of HLA disparity 
associated with TRM. Because the major cause of TRM in 
this study was sepsis, early identification and proper treat-
ment of infections is imperative, if HSCT is performed in 
a patient with high-risk disease using an incompletely match-
ed donor.
  The acceptable Mm level remains controversial. This is 
important in donor selection, when a fully matched donor 
is not available, and a choice must be made between accepting 
a mismatched donor, searching for other sources of stem 
cells or a haploidentical donor, and completely avoiding 
HSCT. Guidelines of the International Histocompatibility 
Working Group (IHWG) state that a full application of the 
rules governing the acceptability of HLA Mms should include 
side-by-side evaluation of ethnically and racially diverse 
transplantation populations (www.ihwg.org). Analysis of 
very large numbers of pairs, characterized at high resolution 
and for whom complete clinical data are available, is of 
crucial importance in addressing locus- and allele-specific 
rules for mismatching [17]. The apparent discrepancy be-
tween our results and those of other studies may be attribut-
able to both study power and ethnicity. A discrepancy be-
tween Korean and other patients may reflect disparities in 
the HLA and non-HLA genetic backgrounds of the more 
homogeneous Korean population compared with more heter-
ogeneous populations. Some HLA alleles and haplotypes are 
distributed at different frequencies among various racial/eth-
nic groups [11]. Thus, specific Mms among HLA-loci may 
be better tolerated within certain ethnic groups. For example, 
a study in Japan suggested that discrepancies of responsible 
HLA locus for aGVHD between ethnically diverse HSCT 
may be explained by the proportions of nonpermissive Mm 
combinations in each HLA locus [18].
  Although several studies have found lower relapse risks, 
of the graft-vs.-leukemia effect in patients with Mms at mul-
tiple loci or at a specific locus [3, 19], we did not find an 
association between HLA disparity and relapse; there may 
be an association of donor/patient HLA mismatching with 
low rate of discontinuation of immunosuppression and pro-
longed immunosuppressive therapy for GVHD compared to 
HLA-matched transplantation. However, as other studies 
did not observe an effect of HLA disparity on relapse, further 
investigations should be conducted to address this issue [4, 
5].
  Our present study had several limitations. First, our patient 
sample was relatively small and heterogeneous, and trans-
plantation protocols were not uniform. Only 3 patients had 
HLA-B Mm; therefore, results should be interpreted with 
caution. However, some analyses regarding HLA-B Mm show 
a P＜0.05. Second, subset comparisons have specific strengths, 
but confounding by Mms at other loci is avoided. Thus, 
this method may overlook a functional role of HLA-A, -B, 
-C, or -DR mismatching that operates only in combination Korean J Hematol 2011;46:11-7.
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with one or more Mms. Membership in groups with double 
and triple Mms was too low to permit statistical analysis. 
Third, we did not analyze the effect of HLA-DP and -DQ, 
which generally showed additive effects when additional 
HLA Mms were present at other loci [6, 20].
  In summary, we showed that outcomes in single-allele 
Mm patients are not equivalent to those in patients with 
8/8 matches. Disparity in HLA class I status, regardless of 
antigen or allele Mm, had adverse effects on survival and 
grade III-IV aGVHD, whereas HLA class II disparities had 
little impact on transplantation outcomes. An increased num-
ber of HLA Mms was associated with higher rates of 
post-transplantation complications, including poorer surviv-
al and increased aGVHD incidence or severity. HLA dis-
parities impacted survival differently when recipients had 
low- or high-risk malignancies. Physicians overseeing HSCT 
for high-risk patients using HLA-mismatched donors should 
avoid and treat infections and associated complications to 
reduce TRM. 
  This study provides useful information regarding the sig-
nificance of HLA matching on outcomes of Korean pediatric 
patients undergoing URD HSCT, thus assisting physicians 
in their search for a suitable donor. Further investigations, 
including analyses of larger cohorts, are warranted to confirm 
the effects of HLA Mms on outcomes of patients undergoing 
HSCT.
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